0001104659-20-001084.txt : 20200103
0001104659-20-001084.hdr.sgml : 20200103
20200103190051
ACCESSION NUMBER: 0001104659-20-001084
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191231
FILED AS OF DATE: 20200103
DATE AS OF CHANGE: 20200103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cawkwell Gail
CENTRAL INDEX KEY: 0001761167
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35668
FILM NUMBER: 20507594
MAIL ADDRESS:
STREET 1: C/O INTERCEPT PHARMACEUTICALS, INC.
STREET 2: 10 HUDSON YARDS, FLOOR 37
CITY: NEW YORK
STATE: NY
ZIP: 10001
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INTERCEPT PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001270073
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 223868459
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 HUDSON YARDS, 37TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10001
BUSINESS PHONE: 646-747-1000
MAIL ADDRESS:
STREET 1: 10 HUDSON YARDS, 37TH FLOOR
CITY: New York
STATE: NY
ZIP: 10001
FORMER COMPANY:
FORMER CONFORMED NAME: INTERCEPT PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20031113
4
1
tm201209d1_4.xml
OWNERSHIP DOCUMENT
X0306
4
2019-12-31
0
0001270073
INTERCEPT PHARMACEUTICALS, INC.
ICPT
0001761167
Cawkwell Gail
C/O INTERCEPT PHARMACEUTICALS, INC.
10 HUDSON YARDS, FLOOR 37
NEW YORK
NY
10001
0
1
0
0
SVP, Med Affairs, Safety & PV
Common Stock
2019-12-31
4
M
0
262
54.63
A
18984
D
Common Stock
2019-12-31
4
S
0
262
125.00
D
18722
D
Common Stock
2019-12-31
4
F
0
349
123.92
D
18373
D
Option to Purchase Common Stock
54.63
2019-12-31
4
M
0
262
0
D
2028-02-12
Common Stock
262
20779
D
This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.
The award is subject to a four-year vesting period, with 25% of shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Start Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Start Date was February 12, 2018.
/s/ Mark Pruzanski, as attorney-in-fact
2020-01-03